➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
McKinsey
Express Scripts
AstraZeneca
Dow

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

ALTOPREV Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Altoprev, and what generic alternatives are available?

Altoprev is a drug marketed by Covis and is included in one NDA.

The generic ingredient in ALTOPREV is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

US ANDA Litigation and Generic Entry Outlook for Altoprev

A generic version of ALTOPREV was approved as lovastatin by ACTAVIS ELIZABETH on December 17th, 2001.

  Start Trial

Summary for ALTOPREV
Drug patent expirations by year for ALTOPREV
Drug Prices for ALTOPREV

See drug prices for ALTOPREV

Recent Clinical Trials for ALTOPREV

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AmgenPhase 4
Brigham and Women's HospitalPhase 4

See all ALTOPREV clinical trials

Pharmacology for ALTOPREV

US Patents and Regulatory Information for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002 RX Yes Yes   Start Trial   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002 RX Yes No   Start Trial   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ALTOPREV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-003 Jun 26, 2002   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-001 Jun 26, 2002   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-004 Jun 26, 2002   Start Trial   Start Trial
Covis ALTOPREV lovastatin TABLET, EXTENDED RELEASE;ORAL 021316-002 Jun 26, 2002   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Colorcon
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.